Abstract 1713P
Background
Many epidemiological studies have shown consistent evidence on the relationship between PA and BC outcomes. Those epidemiological studies have mostly used questionnaires to assess PA instead of objective methods. Unfortunately, the biological mechanisms through which PA regulates BC progression, are not fully outlined. The mediators classically reported to be affected by PA include sex steroid hormones, stress hormones, metabolic hormones (insulin resistance) and inflammatory markers.
Methods
BC survivors, >18 years-old, who had finished their treatment were asked to wear an accelerometer. They also were asked to fill in the International Physical Activity Questionnaire (IPAQ) short-form (SF). Accelerometer generates information about minutes of exercise of different intensity in a week. IPAQ collects the self-reported information about exercise of different intensity also. Assay of neutrophil/lymphocyte ratio (NLR), C reactive protein (CRP), cortisol, estrogens, progesterone, testosterone, androsterone, glucose, insulin, IGF-1, IGFBP-3 was done. Vigorous, MVPA and sedentary time were analysed for each biomarker. Both objective and subjective measures were explored.
Results
84 participants were evaluated. Average moderate and vigorous PA (MVPA) was 275 min/week. Average vigorous physical activity (VPA) was 7.7 min/wk. Sedentary time 3292 min (55h)/wk. Accelerometer measured VPA was associated with NLR (p=0.007). When VPA was self-reported (IPAQ-SF), it was not associated with NLR. We could not find any additional association between biomarkers and physical activity either objectively measured or self-reported.
Conclusions
Accelerometer-measured VPA was associated with a lower NLR in a cohort of active (>150 min/wk MVPA) BC survivors. Other potential consistent associations with inflammatory markers (namely CRP), with self reported vigorous PA, or with MVPA or sedentary time, were not found. No associations with stress, sex or hormones related to insulin resistance were identified. More research is needed to understand the effects of PA on BC progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Ruiz-Casado.
Funding
SEOM-Font Vella.
Disclosure
All authors have declared no conflicts of interest.